Entering text into the input field will update the search result below

Celldex gains 12% on Phase 1 data for urticaria candidate

Feb. 27, 2023 10:42 AM ETCelldex Therapeutics, Inc. (CLDX) StockNVS, RHHBYBy: Dulan Lokuwithana, SA News Editor

Urticaria on the skin. Red spots of an allergic reaction on the skin of a child. Urticaria symptoms close up

SERSOL/iStock via Getty Images

Celldex Therapeutics (NASDAQ:CLDX) added ~12% marking the biggest intraday gain since November after the biotech announced early-stage results for its experimental monoclonal antibody barzolvolimab from patients with the skin condition urticaria.

Citing data from a Phase 1b

Recommended For You

More Trending News

About CLDX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CLDX--
Celldex Therapeutics, Inc.